Prelude Therapeutics to Participate in Three Healthcare Investor Conferences in September

About this update from Prelude Therapeutics Incorporated

WILMINGTON, Del. , Aug. 29, 2023 (GLOBE NEWSWIRE) -- Prelude Therapeutics Incorporated (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced that company executives will participate in three upcoming healthcare investment conferences. Details are as follows: Wells Fargo 18 th Annual Healthcare Conference Boston Kris Vaddi , Ph.D., Chief Executive Officer will participate in a Fireside chat on Wednesday, September 6 , at 4:30 p.m. ET . The live webcast is available here . Dr. Vaddi and Laurent Chardonnet , Chief Financial Officer of Prelude , will host one-on-one meetings at the conference. H. C. Wainwright 25 th Annual Healthcare Investment Conference Dr. Vaddi and Jane Huang , MD, President and Chief Medical Officer will participate in a Fireside chat on Monday, September 11 , at 1:30 p.m. ET . The live webcast is available here . Dr. Vaddi , along with Dr. Huang and Mr. Chardonnet will host one-on-one investor meetings at the conference. Morgan Stanley 21 st Annual Global Healthcare Conference On Tuesday, September 12 , at 4:55 p.m. ET , Dr. Vaddi and Dr. Huang will participate in a Fireside chat. The live webcast is available here . Dr. Vaddi , Dr. Huang and Mr. Chardonnet will conduct one-on-one investor meetings at the conference. About Prelude Therapeutics Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways. The Company’s diverse pipeline is comprised of highly differentiated, potentially best/first-in-class proprietary small molecule compounds aimed at addressing specific pathways for cancers with selectable underserved patients. Prelude’s pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1, PRT2527, a potent and highly selective CDK9 inhibitor, PRT3645 a next generation CDK4/6 inhibitor , PRT3789 an IV administered, potent and highly selective SMARCA2 degrader, and a preclinical oral candidate targeting SMARCA2. For more information, visit our website and follow us on LinkedIn and Twitter . Investor Contact: Lindsey Trickett Vice President, Investor Relations 240.543.7970 [email protected] Media Contact: Helen Shik Shik Communications 617.510.4373 [email protected] Source: Prelude Therapeutics, Inc.

View stock analysis, news, and events for Prelude Therapeutics Incorporated